Markets
News
Analysis
User
24/7
Economic Calendar
Education
Data
- Names
- Latest
- Prev
A:--
F: --
P: --
A:--
F: --
P: --
A:--
F: --
P: --
A:--
F: --
A:--
F: --
A:--
F: --
P: --
A:--
F: --
P: --
A:--
F: --
P: --
A:--
F: --
P: --
A:--
F: --
P: --
A:--
F: --
P: --
A:--
F: --
P: --
A:--
F: --
P: --
A:--
F: --
P: --
A:--
F: --
P: --
A:--
F: --
P: --
A:--
F: --
P: --
A:--
F: --
P: --
A:--
F: --
P: --
A:--
F: --
P: --
A:--
F: --
P: --
A:--
F: --
P: --
A:--
F: --
P: --
A:--
F: --
P: --
A:--
F: --
P: --
A:--
F: --
P: --
A:--
F: --
A:--
F: --
P: --
A:--
F: --
P: --
--
F: --
P: --
--
F: --
P: --
--
F: --
P: --
--
F: --
P: --
--
F: --
P: --
--
F: --
P: --
--
F: --
P: --
--
F: --
P: --
--
F: --
P: --
--
F: --
P: --
--
F: --
P: --
--
F: --
P: --
--
F: --
P: --
--
F: --
P: --
--
F: --
P: --
--
F: --
P: --
--
F: --
P: --
--
F: --
P: --
--
F: --
P: --
--
F: --
P: --
--
F: --
P: --
--
F: --
P: --
--
F: --
P: --
--
F: --
P: --
--
F: --
P: --
--
F: --
P: --
--
F: --
P: --
No matching data
Latest Views
Latest Views
Trending Topics
To quickly learn market dynamics and follow market focuses in 15 min.
In the world of mankind, there will not be a statement without any position, nor a remark without any purpose.
Inflation, exchange rates, and the economy shape the policy decisions of central banks; the attitudes and words of central bank officials also influence the actions of market traders.
Money makes the world go round and currency is a permanent commodity. The forex market is full of surprises and expectations.
Top Columnists
Enjoy exciting activities, right here at FastBull.
The latest breaking news and the global financial events.
I have 5 years of experience in financial analysis, especially in aspects of macro developments and medium and long-term trend judgment. My focus is maily on the developments of the Middle East, emerging markets, coal, wheat and other agricultural products.
BeingTrader chief Trading Coach & Speaker, 8+ years of experience in the forex market trading mainly XAUUSD, EUR/USD, GBP/USD, USD/JPY, and Crude Oil. A confident trader and analyst who aims to explore various opportunities and guide investors in the market. As an analyst I am looking to enhance the trader’s experience by supporting them with sufficient data and signals.
Latest Update
Risk Warning on Trading HK Stocks
Despite Hong Kong's robust legal and regulatory framework, its stock market still faces unique risks and challenges, such as currency fluctuations due to the Hong Kong dollar's peg to the US dollar and the impact of mainland China's policy changes and economic conditions on Hong Kong stocks.
HK Stock Trading Fees and Taxation
Trading costs in the Hong Kong stock market include transaction fees, stamp duty, settlement charges, and currency conversion fees for foreign investors. Additionally, taxes may apply based on local regulations.
HK Non-Essential Consumer Goods Industry
The Hong Kong stock market encompasses non-essential consumption sectors like automotive, education, tourism, catering, and apparel. Of the 643 listed companies, 35% are mainland Chinese, making up 65% of the total market capitalization. Thus, it's heavily influenced by the Chinese economy.
HK Real Estate Industry
In recent years, the real estate and construction sector's share in the Hong Kong stock index has notably decreased. Nevertheless, as of 2022, it retains around 10% market share, covering real estate development, construction engineering, investment, and property management.
Hongkong, China
Ho Chi Minh, Vietnam
Dubai, UAE
Lagos, Nigeria
Cairo, Egypt
White Label
Data API
Web Plug-ins
Affiliate Program
View All
No data
Not Logged In
Log in to access more features
FastBull Membership
Not yet
Purchase
Log In
Sign Up
Hongkong, China
Ho Chi Minh, Vietnam
Dubai, UAE
Lagos, Nigeria
Cairo, Egypt
White Label
Data API
Web Plug-ins
Affiliate Program
Alameda, CA-based Penumbra, Inc. PEN has secured the CE Mark in Europe for its newest computer-assisted vacuum thrombectomy (CAVT) technologies, Lightning Flash 2.0 and Lightning Bolt 7. Lightning Flash 2.0 is the most advanced mechanical thrombectomy system available to address venous and pulmonary thrombus while the Lightning Bolt 7 stands out as the most powerful arterial thrombectomy system in the market.
The latest innovations further enhance the company’s neuro and vascular portfolios.
Likely Trend of PEN Stock Following the Announcement
Following the news, shares of PEN inched up 0.4% to $187.65 at yesterday’s close. With thrombectomy procedures gaining fast popularity globally, Penumbra has been witnessing market share gains, banking on strong customer uptake of its Lightning Bolt and Flash lines.
The latest development is likely to boost European physicians’ trust in considering CAVT as a valuable first-line option to manage conditions such as pulmonary embolism (PE), venous thrombosis and other severe cases. Henceforth, we expect the market sentiment toward the stock to remain positive, driven by this development.
More on Penumbra’s Latest CAVT Technologies
Lightning Flash 2.0 features Penumbra’s Lightning Intelligent Aspiration technology with the latest dual clot detection algorithms, using both pressure and flow-based processes to detect blood clots and blood flow. The catheter is made with MaxID hypotube technology, allowing an inner diameter similar to large-bore catheters while maintaining a lower profile and a soft, atraumatic tip design.
The design facilitates the removal of blood clots with speed, safety and simplicity, allowing physicians to navigate the body’s complex anatomy and deliver high-power aspiration for clot removal with minimal blood loss.
Lightning Bolt 7 uses a new method for removing blood clots called modulated aspiration, which pairs the Lightning Intelligent Aspiration technology with an advanced microprocessor algorithm. When combined, the system is designed to rapidly remove large, fibrous blood clots in the arteries with minimal blood loss, addressing conditions such as acute limb ischemia , hibernating thrombus and visceral occlusions.
Lightning Bolt 7 is engineered to detect the difference between blood clots and blood flow. Additionally, it is designed to break the friction between the catheter and clot by having the computer algorithms rapidly modulate aspiration to quickly fatigue the thrombus and remove the clot from the arteries.
Industry Prospects Favoring Penumbra
A report from Precedence Research valued the thrombectomy devices market at $1.52 billion in 2023 and predicted it to witness a compound annual growth rate of 7.33% through 2033.
The market growth is fueled by the rising incidences of cardiovascular diseases among an aging population, leading to an increasing demand for thrombectomy procedures. Additionally, the devices help prevent life-threatening diseases like stroke, PE and heart attack, among others.
Penumbra’s Other Developments
In June 2024, Penumbra announced the CE Mark and European launch of two advanced neuro access offerings, BMX 81 and BMX 96, designed for neurovascular management of ischemic and hemorrhagic stroke. The announcement follows the launch of three new RED reperfusion catheters (RED 43, RED 72 with SENDit Technology and RED 78) earlier in May.
PEN Stock’s Price Performance
In the past year, PEN’s shares have declined 29.4% against the industry’s 17.6% growth.
PEN’s Zacks Rank and Key Picks
Penumbra currently carries a Zacks Rank #5 (Strong Sell).
Some better-ranked stocks in the broader medical space are Boston Scientific BSX, AxoGen AXGN, and SiBone SIBN, each carrying a Zacks Rank #2 (Buy) at present. You can see the complete list of today’s Zacks #1 Rank (Strong Buy) stocks here.
Boston Scientific’s shares have risen 57.5% in the past year. Estimates for the company’s earnings per share have remained constant at $2.40 in 2024 and $2.71 in 2025 in the past 30 days. BSX’s earnings beat estimates in each of the trailing four quarters, delivering an average surprise of 7.2%. In the last reported quarter, it posted an earnings surprise of 6.9%.
Estimates for AxoGen’s 2024 loss per share have remained constant at 1 cent in the past 30 days. Shares of the company have surged 165.9% in the past year compared with the industry’s 17.6% growth. AXGN’s earnings surpassed estimates in each of the trailing four quarters, the average surprise being 96.5%. In the last reported quarter, it delivered an earnings surprise of 200%.
Estimates for SiBone’s 2024 loss per share have remained constant at 89 cents in the past 30 days. Shares of the company lost 31.4% in the past year against the industry’s 17.6% growth. SIBN’s earnings surpassed estimates in each of the trailing four quarters, the average surprise being 13.4%. In the last reported quarter, it delivered an earnings surprise of 15.4%.
Zacks Investment Research
Inspira Technologies OXY B.H.N. Ltd. IINN has secured an additional U.S. Patent approval for the VORTX orbiting blood oxygenation delivery system, a fundamental technology of the INSPIRA ART (Augmented Respiration Technology) device. With this addition, the total number of claims deemed novel relating to the core technology of the device comes to 32.
The latest development advances blood oxygenation technologies, marking another crucial milestone for the company and underscoring the core technological capabilities of the INSPIRA ART.
Following the news, shares of IINN jumped 5.2% to $1.21 at Friday’s close. Inspira is working on new life support-extending technologies with blood oxygenation and blood monitoring technologies, aiming to transform the respiratory treatment space. We expect the market sentiment toward the stock to remain positive around this development.
Significance of IINN’s INSPIRA ART Device Featuring VORTX
The VORTX system aims to oxygenate blood without fiber membranes, starkly differing from the existing fiber technologies for blood oxygenation. The traditional fiber oxygenators force blood to flow through multiple fiber layers, causing harmful turbulence, friction and shear forces. Due to the fiber fabric's high resistance to blood flow, it creates pressure differences that can severely damage blood components, causing hemolysis, white blood cell damage, inflammatory and immune system activation and blood clotting.
IINN’s INSPIRA ART device can make a major impact on the $19 billion mechanical ventilation market. It offers a potential alternative to nearly 20 million intensive care unit patients with respiratory failure each year, with many relying on mechanical ventilators, by maintaining stable oxygen saturation levels without the need for ventilators while allowing patients to remain awake during treatment. Equipped with HYLA real-time continuous blood monitoring technology, the system can rapidly detect changes in patient conditions so that physicians can make more informed decisions.
Inspira had obtained the FDA’s 510(k) clearance for the INSPIRA ART100 system for use in Cardiopulmonary Bypass procedures, along with the Israeli AMAR (Medical Device Division of the Israeli Ministry of Health) certification for both Extra-Corporeal Membrane Oxygenation and Cardiopulmonary Bypass procedures. More products are currently in the development phase, including the INSPIRA ART500 or Gen 2, the INSPIRA Cardi-ART portable modular device and the HYLA blood sensor.
Industry Prospects Favoring Inspira
A Data Bridge Market Research report valued the global oxygen delivery system market at $12.94 billion in 2021, forecasted to witness a compound annual growth rate of 6.3% through 2029.
The market growth is expected to be driven by the growing prevalence of diseases such as obesity, hypertension, chronic obstructive pulmonary disease (COPD), asthma, respiratory distress syndrome, pneumonia, cystic fibrosis and associated complications in cardiac arrest. Developed healthcare infrastructure and expanded insurance coverage globally should boost the market.
Recent Developments Within Inspira
Last month, Inspira secured the FDA’s listing for the INSPIRA CART, which has been tailored for use with the INSPIRA ART100 system. The INSPIRA CART is designed for use in operating rooms during Cardiopulmonary Bypass procedures in the United States. It is currently classified as a Class I Medical Device and 510(K) Exempt under the FDA code for cardiopulmonary bypass accessory equipment.
IINN Price Performance
In the past year, IINN shares have fallen 19.4% against the industry’s 17.6% growth.
IINN’s Zacks Rank and Key Picks
Inspira currently carries a Zacks Rank #3 (Hold).
Some better-ranked stocks in the broader medical space are Boston Scientific BSX, AxoGen AXGN and SiBone SIBN, each carrying a Zacks Rank #2 (Buy) at present. You can see the complete list of today’s Zacks #1 Rank (Strong Buy) stocks here.
Boston Scientific’s shares have risen 57.2% in the past year. Estimates for the company’s earnings per share have remained constant at $2.40 in 2024 and $2.71 in 2025 in the past 30 days. BSX’s earnings beat estimates in each of the trailing four quarters, delivering an average surprise of 7.2%. In the last reported quarter, it posted an earnings surprise of 6.9%.
Estimates for AxoGen’s 2024 loss per share have remained constant at 1 cent in the past 30 days. Shares of the company have surged 156.8% in the past year compared with the industry’s growth of 17.6%. AXGN’s earnings surpassed estimates in each of the trailing four quarters, the average surprise being 96.5%. In the last reported quarter, it delivered an earnings surprise of 200%.
Estimates for SiBone’s 2024 loss per share have remained constant at 89 cents in the past 30 days. Shares of the company have dropped 30.5% in the past year against the industry’s 17.6% growth. SIBN’s earnings surpassed estimates in each of the trailing four quarters, the average surprise being 13.4%. In the last reported quarter, it delivered an earnings surprise of 15.4%.
Zacks Investment Research
Inogen, Inc. INGN is well-poised for growth in the coming quarters, courtesy of high prospects in the portable oxygen concentrator (POC) space. The optimism, led by solid first-quarter 2024 performance and a strong product portfolio, seems justified. However, issues like stiff competition and forex volatility are major downsides.
The Zacks Rank #2 (Buy) company’s shares have risen 106.4% year to date compared with 9.2% growth of the industry. The S&P 500 has increased 17.7% during the same time frame.
The renowned provider of POCs has a market capitalization of $268.7 million. The company projects 56.6% growth for 2024 and expects to witness continued improvements in its business. Inogen’s P/S ratio of 0.8X makes its valuation attractive compared with the industry’s 3.1X.
Let us delve deeper.
High Prospects in the POC Space: We are optimistic about the POCs’ superiority over conventional oxygen therapy (known as the delivery model). Inogen primarily develops, manufactures and markets innovative POCs to deliver supplemental long-term oxygen therapy (LTOT) to patients suffering from chronic respiratory conditions.
INGN’s proprietary Inogen One and Inogen Rove systems concentrate the air around the patient to offer a source of supplemental oxygen anytime, anywhere, with a battery that can be plugged into an outlet. Per a report by Data Bridge Market Research, the POCs market was valued at $1.58 billion in 2022 and is anticipated to reach $3.03 billion by 2030 at a CAGR of 8.5%.
Product Portfolio: We are optimistic about Inogen’s expanding product portfolio. The company has received the FDA 510(k) clearance for the Inogen Rove 4, which is set to be launched soon. The Rove 4 will offer patients a new flow setting compared to the earlier versions, a service life of up to eight years and highest oxygen production. It is also the lightest POC in the market.
Inogen launched Rove 6 in the U.S. market in July 2023. The Inogen Rove 6 is the first POC with an expected service life of eight years.
Strong Q2 Results: Inogen’s robust year-over-year uptick in domestic and international business-to-business sales buoys optimism. Solid year-over-year top and bottom-line performances were encouraging. Further, the expansion of the adjusted gross margin bodes well.
On the earnings call, management confirmed that targeting hospitals in addition to individual practitioners through its rental business gave earlier access to patients in their care pathway, increasing the duration over which INGN can receive payments. By expanding its scale, efficiency and throughput in the rental channel, Inogen expects to drive higher profitability over time.
The company is also seeing cost benefits in the form of lower sales and marketing expenses on the back of the recent exit of its third-party relationship in the rental channel. These factors raise optimism about the stock.
Risks
Stiff Competition: The LTOT market has intense industrial competition. Inogen faces competition from several POC producers and distributors as well as suppliers of other LTOT services, such as home delivery of oxygen cylinders or tanks. Given the relatively straightforward regulatory path in the oxygen therapy device manufacturing market, Inogen expects the industry to become increasingly competitive in the future.
Forex Volatility: The foreign market accounts for a sizeable amount of INGN's income. Management anticipates overseas revenues to continue to be erratic due to the distributor's size and timing. In the near future, INGN also expects unfavorable foreign exchange rates to hinder revenue growth since the U.S. dollar is increasing relative to the euro and other foreign currencies.
Estimate Trend
Inogen has been witnessing an improving estimate revision trend for 2024. In the past 60 days, the Zacks Consensus Estimate for its loss per share has narrowed 11.4% to $1.95.
The Zacks Consensus Estimate for 2024 revenues is pegged at $327 million, suggesting a 3.6% decline from the year-ago reported number.
Inogen, Inc Price
Inogen, Inc price | Inogen, Inc Quote
Key Picks
Some other top-ranked stocks in the broader medical space are Boston Scientific BSX, AxoGen AXGN and SiBone SIBN, each carrying a Zacks Rank #2 at present. You can see the complete list of today’s Zacks #1 Rank (Strong Buy) stocks here.
Boston Scientific’s shares have risen 58.4% in the past year. Estimates for the company’s earnings per share have remained constant at $2.40 for 2024 and $2.71 for 2025 in the past 30 days. BSX’s earnings beat estimates in each of the trailing four quarters, delivering an average surprise of 7.2%. In the last reported quarter, it posted an earnings surprise of 6.9%.
Estimates for AxoGen’s 2024 loss per share have remained constant at 1 cent in the past 30 days. Shares of the company have surged 145% in the past year compared with the industry’s growth of 15.5%. AXGN’s earnings surpassed estimates in each of the trailing four quarters, the average surprise being 96.5%. In the last reported quarter, it delivered an earnings surprise of 200%.
Estimates for SiBone’s 2024 loss per share have remained constant at 89 cents in the past 30 days. Shares of the company have lost 30.4% in the past year against the industry’s 15.5% growth. SIBN’s earnings surpassed estimates in each of the trailing four quarters, the average surprise being 13.4%. In the last reported quarter, it delivered an earnings surprise of 15.4%.
Zacks Investment Research
OrthoPediatrics Corp. KIDS recently launched its Enabling Technologies division, which will leverage the company's core mission of addressing unmet pediatric needs in orthopedics.
The advancement with the latest launch positions OrthoPediatrics at the forefront of the pediatric digital health and enabling technologies sectors.
Following the announcement, shares of OrthoPediatrics rose 2.15% to $32.38 on Friday. The company continues to gain a high level of synergies from its various latest developments within the pediatric digital health space. Accordingly, we expect market sentiment to continue to remain positive around this announcement.
More on OrthoPediatrics’ Enabling Technologies Division
Led by industry veteran Kevin Unger, this new division is set to differentiate OrthoPediatrics' core business, generate sustainable revenue growth, and gain access to new markets and specialties beyond orthopedics.
The company has made significant strides in the field through its distribution of the 7D Flash Navigation System. Additionally, it collaborated with 3D Side, S.A. for patient-specific cutting guides. These innovations have laid a strong foundation for the Enabling Technologies division.
OrthoPediatrics’ Business Advancements
Given the success of the above-mentioned developments, KIDS is all set to launch its two groundbreaking technology platforms. First, Playbook is a cutting-edge surgical workflow and outcome optimization platform. It is designed to enhance surgical planning, collaboration and intraoperative workflow. Playbook is aimed at revolutionizing how surgeries are planned and executed, potentially resulting in improved outcomes and more efficient processes.
Second, Robotic-Assistance is for Cochlear Implant Technology.OrthoPediatrics partnered with iotaMotion, Inc. to bring a robotic-assisted insertion system to enhance cochlear implant surgery. This technology offers a slow electrode array insertion that is agnostic to cochlear implant manufacturers, providing greater control and precision for pediatric patients.
Other Recent Developments by OrthoPediatrics
In May, the company received the “Breakthrough Device” designation from the Food and Drug Administration for its new eLLi surgical device. eLLi is an implant designed to address severe pathology associated with early onset scoliosis (EOS), which can be associated with thoracic insufficiency, a potentially life-threatening condition. This innovative product should be a great addition to the suite of products for pediatric patients with scoliosis.
Earlier this year, OrthoPediatrics launched a new RESPONSE Rib and Pelvic Fixation system to treat children with EOS. The system represents OrthoPediatrics' first solution to treat patients at risk of thoracic insufficiency syndrome. The new addition to the RESPONSE portfolio includes implants and instruments for rib and pelvic fixation, and associated devices to connect the fixation points.
Industry Prospects Favor OrthoPediatrics
Per a Grand View Research report, the global pediatric orthopedic devices market was valued at $3.83 billion in 2023 and is projected to witness a CAGR of 11.0% from 2024 to 2030.
Primary factors behind the projected market surge include growing awareness of orthopedic conditions in children and the rise in congenital & developmental disorders. Furthermore, innovations such as adjustable & customizable devices and improved materials for better functionality & safety are fueling market growth.
Henceforth, OrthoPediatrics' latest announcement is well-timed.
KIDS’ Price Performance
Year to date, shares of KIDS have risen 0.7% compared with the industry’s 9.3% growth.
KIDS’ Zacks Rank and Other Key Picks
KIDS currently carries a Zacks Rank #2 (Buy).
Some other top-ranked stocks in the broader medical space are Intuitive Surgical ISRG, TransMedics Group TMDX and Boston Scientific BSX. While Intuitive Surgical and TransMedics currently sport a Zacks Rank #1 (Strong Buy) each, Boston Scientificcarries a Zacks Rank #2. You can see the complete list of today’s Zacks #1 Rank stocks here.
Intuitive Surgical’s shares have surged 64.3% in the past year. Estimates for the company’s earnings have moved north 5.1% to $1.65 per share for 2024 in the past 30 days.
ISRG’s earnings beat estimates in each of the trailing four quarters, delivering an average surprise of 8.97%. In the last reported quarter, it posted an earnings surprise of 16.34%.
Estimates for TransMedics’ 2024 EPS have moved up 125% to 27 cents in the past 30 days. Shares of the company have soared 156.9% in the past year compared with the industry’s 17.5% growth.
TMDX’s earnings surpassed estimates in each of the trailing four quarters, the average surprise being 287.50%. In the last reported quarter, it delivered an earnings surprise of 66.67%.
Estimates for Boston Scientific’s 2024 EPS have increased 1.7% to $2.40 in the past 30 days. In the past year, shares of BSX have risen 57.2% compared with the industry’s 19.5% growth.
In the last reported quarter, BSX delivered an earnings surprise of 6.90%. Its earnings surpassed estimates in each of the trailing four quarters, the average surprise being 7.18%.
Zacks Investment Research
Phibro Animal Health’s PAHC diversified product portfolio and wide presence in key growth areas bolster our confidence in the stock. The stock carries a Zacks Rank #2 (Buy) currently.
Factors Driving PAHC's Growth
Phibro’s key animal health products, including Medicated Feed Additives (MFAs) and nutritional specialty products, enhance animal nutrition. The company’s leading product franchise, Stafac/V-Max/Eskalin, is approved in more than 30 countries for use in poultry and swine. Similarly, the company’s nutritional product offerings, such as OmniGen-AF and Animate, are used increasingly in the global dairy industry. The company also manufactures vaccines, which protect animals from both viral and bacterial disease challenges. Moreover, the company is committed to developing its companion animal business and pipeline. These are key growth areas for Phibro both in the short and medium term, and it has been actively investing in these growth drivers to achieve its targets.
During the fiscal fourth quarter, Phibro entered into a purchase and sale agreement with Zoetis to acquire the latter’s MFA product portfolio, certain water-soluble products and related assets. The company anticipates to complete the transaction in the initial phase of fiscal 2025.
Phibro’s existing operations and established sales, marketing and distribution network in over 80 countries provide it ample scope to take advantage of global growth opportunities. Outside the United States, Phibro’s global footprint extends to key high-growth regions (countries where the livestock production growth rate is expected to be higher than the average growth rate), including Brazil and other countries in South America, China, India and Southeast Asia, Mexico, Turkey, Australia, Canada, Poland and other Eastern European countries and South Africa and other countries in Africa.
At the end of fiscal 2024, the company’s operations in countries outside of the United States contributed approximately 42.5% of its total revenues. Our model forecasts sales in Latin America and Canada to improve 10% in fiscal 2026. For fiscal 2025, a sales improvement of 10.8% and 14% is expected from Europe, Middle East & Africa, and Asia Pacific regions, respectively.
Phibro Animal Health Corporation Price
Phibro Animal Health Corporation price | Phibro Animal Health Corporation Quote
The stock has gained 63.4% in a year compared with the industry’s 18.4% rise. With the company strategically expanding through innovation and acquisitions, as well as expanding its business footprint, we expect the stock to continue its upward movement in the coming days.
Concerning Factor for PAHC
In a challenging macro environment, the Mineral Nutrition business has been facing adverse movements in commodity prices and inventory positions. For fiscal 2024, Mineral Nutrition growth was flat year over year. While margins may return to some historical levels as the fiscal year progresses, Phibro anticipates volume recovery might be longer. Meanwhile, sales of Performance Products during fiscal 2024 also decreased 10% year over year owing to the reduced demand for personal care product ingredients and industrial chemicals. Our model suggests a sales decline of 4.9% and 6% in Nutritional Specialty and Performance Products, respectively, for fiscal 2025.
Other Key Picks
Other top-ranked stocks in the broader medical space are Boston Scientific BSX, AxoGen AXGN and SiBone SIBN, each carrying a Zacks Rank #2 at present. You can see the complete list of today’s Zacks #1 Rank (Strong Buy) stocks here.
Boston Scientific’s shares have risen 52.2% in the past year. Estimates for the company’s earnings per share have remained constant at $2.40 for 2024 and at $2.71 for 2025 in the past 30 days. BSX’s earnings beat estimates in each of the trailing four quarters, delivering an average surprise of 7.2%. In the last reported quarter, it posted an earnings surprise of 6.9%.
Estimates for AxoGen’s 2024 loss per share have narrowed to 1 cent from 19 cents in the past 30 days. Shares of the company have surged 126.3% in the past year compared with the industry’s growth of 13.9%. AXGN’s earnings surpassed estimates in each of the trailing four quarters, the average surprise being 96.5%. In the last reported quarter, it delivered an earnings surprise of 200%.
Estimates for SiBone’s 2024 loss per share have remained constant at 89 cents in the past 30 days. Shares of the company have plunged 27.4% in the past year against the industry’s 13.9% growth. SIBN’s earnings surpassed estimates in each of the trailing four quarters, the average surprise being 13.4%. In the last reported quarter, it delivered an earnings surprise of 15.4%.
Zacks Investment Research
QIAGEN N.V. QGEN announced the expansion of its strategic partnership with Bio-Manguinhos/Fiocruz, a leading vaccines and diagnostics supplier to the Brazilian Ministry of Health. Initiated in 2009, the expanded collaboration allows Bio-Manguinhos to launch an advanced PCR (Polymerase Chain Reaction)-based molecular screening platform to detect malaria alongside HIV, hepatitis B and C virus, a capability previously unavailable in Brazil’s blood donation program. The recent development will also support epidemiological surveillance of Brazil’s ongoing dengue epidemic by composing dengue molecular kits based on unique collaborative chemistry.
Following the news, shares of QGEN declined 0.6% to $45.57 at yesterday’s close. However, the company is accelerating the introduction of cutting-edge products and capabilities to the market through tailored OEM (Original Equipment Manufacturer) offerings and extensive support for companies in the life sciences research, biotechnology and diagnostics sectors. Hence, we expect the market sentiment to remain positive around this news.
More on QIAGEN’s Expanded Collaboration
Brazil’s national blood screening program was launched in 2010, the largest blood donation safety initiative in its history. The advanced Brazilian Nucleic Acid Test (NAT Plus) platform, which utilizes QIAGEN’s PCR reagents, was recently rolled out as part of the program. The latest advancement improves transfusional safety by detecting malaria and closing the “diagnostic window” between the time of infection and laboratory diagnosis. Since 2009, QIAGEN and Bio-Manguinhos have been partnering to equip the national blood screening program with advanced molecular testing solutions.
Presently, the NAT Plus platform is operational in 30 laboratories and is critical to safeguarding blood supplies in regions where these diseases are not endemic. It supports health surveillance within the blood transfusion system, engaging over 300 trained professionals across 14 chemotherapy centers and processing 3.5 million samples annually. QIAGEN will supply critical molecular biology technologies, custom solutions and comprehensive training to facilitate Brazil’s public health initiative. Under the terms of this agreement, the company’s solutions will be included in the screening kits and private labeled under the Bio-Manguinhos’ brand.
The collaboration also emphasizes the pivotal role of QIAGEN’s Strategic Partnerships and OEM Division, supporting more than 400 partners globally.
Industry Prospects Favoring QGEN
A report from the SkyQuest Technology Group valued the global PCR molecular diagnostics market at $17.8 billion in 2021, forecasted to witness a compound annual growth rate of 12.8% through 2030. The market is a fast-growing sector, driven by the need for accurate and timely diagnostic testing. The rising incidences of infectious diseases, genetic disorders and cancer create a substantial market opportunity for PCR molecular diagnostics. Furthermore, the growing awareness and adoption of precision medicine approaches further contribute to the market's potential for targeted therapies and personalized treatment regimens.
QIAGEN’s Recent Developments
Last week, QIAGEN teamed up with Eli Lilly and Company to support the development of a QIAstat-Dx in-vitro diagnostic to detect APOE (apolipoprotein E) genotypes in the diagnosis of Alzheimer’s disease. The panel will be integrated with QIAGEN's multiplex testing platform QIAstat-Dx, marking the first publicly disclosed collaboration for a clinical application of the system in neurodegenerative diseases and adding to two more collaborations for diagnostics development programs with other companies.
QGEN's Price Performance
In the past year, QGEN shares have gained 6% against the industry’s 2.2% fall.
QGEN’s Zacks Rank and Key Picks
QIAGEN currently carries a Zacks Rank #3 (Hold).
Some better-ranked stocks in the broader medical space are Boston Scientific BSX, AxoGen AXGN and SiBone SIBN, each carrying a Zacks Rank #2 (Buy) at present. You can see the complete list of today’s Zacks #1 Rank (Strong Buy) stocks here.
Boston Scientific’s shares have gained 58.4% in the past year. Estimates for the company’s earnings per share have remained constant at $2.40 in 2024 and $2.71 in 2025 in the past 30 days. BSX’s earnings beat estimates in each of the trailing four quarters, delivering an average surprise of 7.2%. In the last reported quarter, it posted an earnings surprise of 6.9%.
Estimates for AxoGen’s 2024 loss per share have remained constant at 1 cent in the past 30 days. Shares of the company have surged 145% in the past year compared with the industry’s growth of 15.5%. AXGN’s earnings surpassed estimates in each of the trailing four quarters, the average surprise being 96.5%. In the last reported quarter, it delivered an earnings surprise of 200%.
Estimates for SiBone’s 2024 loss per share have remained constant at 89 cents in the past 30 days. Shares of the company have dropped 30.4% in the past year against the industry’s 15.5% growth. SIBN’s earnings surpassed estimates in each of the trailing four quarters, the average surprise being 13.4%. In the last reported quarter, it delivered an earnings surprise of 15.4%.
Zacks Investment Research
CVS Health Corporation CVS recently introduced hormonal contraceptive prescribing service at CVS Pharmacy locations in Massachusetts. Under the service, a CVS pharmacist will evaluate women interested in receiving a birth control prescription and those who are clinically eligible will receive the same.
With the latest launch, the company leaped toward lowering barriers that prevent women from getting the birth control they need. The initiative also helped address the disparities in contraceptive access for those in historically underserved areas.
Following the announcement, shares of CVS Health rose 2.5% to $57.53 yesterday. The company continues to gain a high level of synergies from its various latest launches through CVS Pharmacy. Accordingly, we expect market sentiment to continue to remain positive around this development.
Importance of CVS’ Birth Control Prescribing Service
Millions of women in the United States live with insufficient access to birth control methods. One in three women faces trouble getting prescriptions for birth control. Hormonal birth control is one of the safest and most effective ways to prevent unplanned pregnancy and support family planning. However, many women find it difficult to obtain the medicine in Massachusetts.
Prescription of hormonal contraceptive was authorized as part of the Massachusetts 2024 State Budget. Enabling pharmacists to prescribe hormonal birth control is an important step toward addressing disparities in access to basic, necessary reproductive healthcare.
The new birth control prescribing service at CVS Pharmacy is aimed to help women in Massachusetts with increased access to birth control. It should further support women's unique healthcare needs. Nearly 400 CVS Pharmacy locations in Massachusetts are offering birth control prescribing services.
How CVS Health’s Birth Control Prescribing Service Works
Patients interested in birth control can visit any Massachusetts CVS Pharmacy location and ask for a birth control consultation with a pharmacist. Those aged 18 and older are eligible for a consultation with a CVS pharmacist. The pharmacist will discuss the results of the health screening with the patient and determine their eligibility to receive birth control at the pharmacy. If eligible, the pharmacist will review different hormonal birth control options available and choose an appropriate therapy for the patient.
Recent Development by CVS Health
In May, the company launched Well Market, a new store-brand consumables line featuring snacks, beverages and groceries. Well Market brings 40 delicious new snacks, beverages and groceries to the shelves of CVS Pharmacy stores nationwide. In addition, the existing Gold Emblem, Gold Emblem abound and Big Chill product lines are expected to be brought under the Well Market umbrella over time.
Industry Prospects Favor CVS Health
Per a Fortune Business Insights report, the global contraceptive drugs market size was valued at $18.57 billion in 2023 and is projected to grow from $19.80 billion in 2024 to $37.22 billion by 2032 at a CAGR of 8.2%.
The primary factors influencing market growth include growing awareness regarding contraceptive drugs and available reimbursement policies in developed countries.
Henceforth, CVS Health’s recently launched birth control prescribing service is well-timed.
Price Performance by CVS Health
In the past year, shares of CVS have lost 17.7% compared with the industry’s 28% decline.
CVS’ Zacks Rank and Key Picks
CVS Health currently carries a Zacks Rank #4 (Sell).
Some better-ranked stocks in the broader medical space are Intuitive Surgical ISRG, TransMedics Group TMDX and Boston ScientificBSX. While Intuitive Surgical and TransMedics currently sport a Zacks Rank #1 (Strong Buy) each, Boston Scientificcarries a Zacks Rank #2 (Buy). You can see the complete list of today’s Zacks #1 Rank stocks here.
Intuitive Surgical’s shares have surged 62.2% in the past year. Estimates for the company’s earnings have moved north 5.1% to $1.65 per share for 2024 in the past 30 days.
ISRG’s earnings beat estimates in each of the trailing four quarters, delivering an average surprise of 8.97%. In the last reported quarter, it posted an earnings surprise of 16.34%.
Estimates for TransMedics’ 2024 EPS have moved up 125% to 27 cents in the past 30 days. Shares of the company have soared 143.8% in the past year compared with the industry’s 15.8% growth.
TMDX’s earnings surpassed estimates in each of the trailing four quarters, the average surprise being 287.50%. In the last reported quarter, it delivered an earnings surprise of 66.67%.
Estimates for Boston Scientific’s 2024 EPS have increased 1.7% to $2.40 in the past 30 days. In the past year, shares of BSX have risen 55.9% compared with the industry’s 18.3% growth.
In the last reported quarter, BSX delivered an earnings surprise of 6.90%. Its earnings surpassed estimates in each of the trailing four quarters, the average surprise being 7.18%.
Zacks Investment Research
White Label
Data API
Web Plug-ins
Poster Maker
Affiliate Program
The risk of loss in trading financial instruments such as stocks, FX, commodities, futures, bonds, ETFs and crypto can be substantial. You may sustain a total loss of the funds that you deposit with your broker. Therefore, you should carefully consider whether such trading is suitable for you in light of your circumstances and financial resources.
No decision to invest should be made without thoroughly conducting due diligence by yourself or consulting with your financial advisors. Our web content might not suit you since we don't know your financial conditions and investment needs. Our financial information might have latency or contain inaccuracy, so you should be fully responsible for any of your trading and investment decisions. The company will not be responsible for your capital loss.
Without getting permission from the website, you are not allowed to copy the website's graphics, texts, or trademarks. Intellectual property rights in the content or data incorporated into this website belong to its providers and exchange merchants.